RDRyan Donnelly

Ryan Donnelly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ryan Donnelly has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Deciphering the Role of Fluorodeoxyglucose-Positron Emission Tomography/CT Imaging in the Management of Sarcoidosis

    by Ryan Donnelly, Alessandro N. Franciosi, Sarah H. Forde, Michael McDermott, Michael P. Keane, David J. Murphy, Emmet E. McGrath, Cormac McCarthy


  • Meta-analysis of 18F-FDG PET/CT in diagnosis and prognostic evaluation of thoracic sarcoidosis

    by Ryan Donnelly, Michael Mc Dermott, Gerry Mc Manus, Alessandro N. Franciosi, Michael P Keane, Emmet E Mc Grath, Cormac Mc Carthy, David J Murphy

    18F-Fluorodeoxyglucose (FDG) PET/CT is emerging as a tool in the diagnosis and evaluation of thoracic sarcoidosis, however, there is limited consensus regarding its diagnostic performance and prognostic value. A meta-analysis was conducted with publication databases searched up to and including September 2023. 1,355 studies were screened, with 17 (n=708 patients) suitable based on their assessment of diagnostic performance or prognostic value of FDG-PET/CT. Forest plots of pooled sensitivity and specificity were generated to assess diagnostic performance and pooled change in SUVmax. These were correlated with changes in pulmonary function tests (PFTs) and quality-of-life. FDG-PET/CT for the diagnosis of thoracic sarcoidosis (6 studies, n=400) had a pooled sensitivity of. 971 (95%CI 0.909 – 1.000, p=<.001), with a specificity (1 study, n=169) of. 873 (95%CI. 845 –. 920). 11 studies were suitable for prognostic analysis (n=308) with a pooled reduction in pulmonary SUVmax of 4.538 (95%CI 5.653 – 3.453, p=<.001) following treatment. PFTs showed improvement following treatment with an increase in percentage of predicted forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) of 7.346% (95%CI 2.257 – 12.436, p=.005) and 3.464% (95%CI -0.205 – 7.132, p=.064), respectively. Reduction in SUVmax strongly correlated with improvement in FVC (r =.644, p<.001) and DLCO (r =.582, p<.001). QOL indicators improved in 75% of the studies assessed (4 studies, n=116). FDG-PET/CT has a high diagnostic performance in thoracic sarcoidosis. Relative change in FDG-PET/CT SUVmax correlated with improvements in PFTs and QOL indicators and may be useful in guiding treatment response.

  • Late Breaking Abstract - Deciphering disagreement: sarcoidosis management and the role of FDG-PET/CT

    by Ryan Donnelly, Alessandro N. Franciosi, Sarah Forde, Michael Mcdermott, Michael P. Keane, Emmet E. Mcgrath, David J. Murphy, Cormac Mccarthy

    Background: Fluoro-2-deoxyglucose-18 (FDG) positron emission tomography (PET/CT) is a novel and effective method of identifying sites of active sarcoidosis. However, the role of FDG-PET/CT in predicting treatment response and guiding therapy, is yet to be completely understood. Physician agreement on FDG-PET/CT utility and management was assessed in this publication through a series of sarcoidosis case vignettes. Methods: Survey responders were presented with a series of anonymised sarcoidosis case vignettes. The perceived utility of FDG-PET/CT in each case, as well as the ultimate treatment decision following provision of FDG-PET/CT results was retained. Rater inter-agreement was assessed overall and per case vignette specialty using Krippendorff’s alpha. Results: Responders (n=215) were predominantly respiratory physicians (86.78%) experienced in sarcoidosis management (94.39%), many with >20 years’ experience (32.66%). The overall inter-rater agreement assessment of all cases was poor (α=0.419). Rater agreement when filtered for case subspecialty was also poor for all cases of cardiac (α=0.567), respiratory (α=0.347) and multi-system sarcoidosis (α=0.286). FDG-PET/CT imaging was more frequently endorsed for cardiac than pulmonary cases (83% vs. 47%). Immunosuppression was increased in over 80% of cardiac cases, while current treatment plans were typically maintained for pulmonary cases. Conclusion: Our results indicate a low agreement between respiratory physicians and their management of pulmonary sarcoidosis following FDG-PET/CT. This highlights a need for further research and clarity over the role of FDG-PET/CT in the therapeutic management of pulmonary sarcoidosis.


  • Open Access

    Meta-analysis of [18F]FDG-PET/CT in pulmonary sarcoidosis

    by Ryan Donnelly, Michael McDermott, Gerry McManus, Alessandro N. Franciosi, Michael P. Keane, Emmet E. McGrath, Cormac McCarthy, David J. Murphy

    Background: 18F-Fluorodeoxyglucose (FDG) PET/CT is emerging as a tool in the diagnosis and evaluation of pulmonary sarcoidosis, however, there is limited consensus regarding its diagnostic performance and prognostic value. Method: A meta-analysis was conducted with PubMed, Science Direct, MEDLINE, Scopus, and CENTRAL databases searched up to and including September 2023. 1355 studies were screened, with seventeen (n = 708 patients) suitable based on their assessment of the diagnostic performance or prognostic value of FDG-PET/CT. Study quality was assessed using the QUADAS-2 tool. Forest plots of pooled sensitivity and specificity were generated to assess diagnostic performance. Pooled changes in SUVmax were correlated with changes in pulmonary function tests (PFT). Results: FDG-PET/CT in diagnosing suspected pulmonary sarcoidosis (six studies, n = 400) had a pooled sensitivity of 0.971 (95%CI 0.909–1.000, p = < 0.001) and specificity of 0.873 (95%CI 0.845–0.920)(one study, n = 169). Eleven studies for prognostic analysis (n = 308) indicated a pooled reduction in pulmonary SUVmax of 4.538 (95%CI 5.653–3.453, p = < 0.001) post-treatment. PFTs displayed improvement post-treatment with a percentage increase in predicted forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) of 7.346% (95%CI 2.257–12.436, p = 0.005) and 3.464% (95%CI -0.205–7.132, p = 0.064), respectively. Reduction in SUVmax correlated significantly with FVC (r = 0.644, p < 0.001) and DLCO (r = 0.582, p < 0.001) improvement. Conclusion: In cases of suspected pulmonary sarcoidosis, FDG-PET/CT demonstrated good diagnostic performance and correlated with functional health scores. FDG-PET/CT may help to guide immunosuppression in cases of complex sarcoidosis or where treatment rationalisation is needed. Clinical relevance statement: FDG-PET/CT has demonstrated a high diagnostic performance in the evaluation of suspected pulmonary sarcoidosis with radiologically assessed disease activity correlating strongly with clinically derived pulmonary function tests. Key Points: In diagnosing pulmonary sarcoidosis, FDG-PET/CT had a sensitivity and specificity of 0.971 and 0.873, respectively. Disease activity, as determined by SUVmax, reduced following treatment in all the included studies. Reduction in SUVmax correlated with an improvement in functional vital capacity, Diffusion Capacity of the Lungs for Carbon Monoxide, and subjective health scoring systems.